



Antenatal corticosteroids for threatened labor facilitate thyroid maturation among preterm neonates

Journal:	<i>Clinical Endocrinology</i>
Manuscript ID	CEN-2020-000290.R3
Manuscript Type:	3 Original Article - Australia, Japan, SE Asia
Date Submitted by the Author:	n/a
Complete List of Authors:	Hanaoka, Shintaro; Kyoto University Graduate School of Medicine Faculty of Medicine, Pediatrics Iwanaga, Kougorou; Fac. Medicine, Kyoto University, Pediatrics Tomotaki, Seiichi; Kyoto University Graduate School of Medicine Faculty of Medicine, Pediatrics Niwa, Fusako; Kyoto university, Pediatrics; Takita, Junko; Kyoto University Graduate School of Medicine Faculty of Medicine, Pediatrics Kawai, Masahiko; Fac. Medicine, Kyoto University, Pediatrics
Key Words:	antenatal corticosteroids, preterm, Thyroid, Cortisol < Hormones/related: < Adrenal, Thyrotropin-Releasing Hormone < Hormones/related: < Hypothalamus




Figure 1. Flowchart of subject enrollment

338x190mm (96 x 96 DPI)

Antenatal corticosteroids for threatened labor facilitate thyroid maturation among preterm neonates

Antenatal steroids induce thyroid maturation

Shintaro Hanaoka, MD, Kogoro Iwanaga, MD, Seiichi Tomotaki, MD, Fusako Niwa, MD, PhD, Junko

Takita, MD, PhD, Masahiko Kawai, MD, PhD

Department of Pediatrics, Graduate School of Medicine, Kyoto University, 54 Kawara-machi, Shogoin,

Sakyo-ku, Kyoto 606-8507, Japan.

Tel.: +81 75 751 3554; Fax: +81 75 752 3638

Corresponding Author: Shintaro Hanaoka, Department of Pediatrics, Graduate School of Medicine, Kyoto

University, 54 Kawara-machi, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.

Tel.: +81 75 751 3554. Fax: +81 75 752 3638. E-mail: hanaokas@kuhp.kyoto-u.ac.jp

Acknowledgments: We thank James Cummins, PhD, from EDANZ Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

Word count: 2090 words

Conflict of interest:

The authors do not declare any conflict of interest or financial involvement with this manuscript.

23

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Abstract

Objective:

To examine the effect of Antenatal corticosteroids (ANS) on the maturation of thyroid function in the preterm infants.

Context:

ANS reduce mortality and morbidities in preterm neonates. Organ maturation by the glucocorticoids is the key, at least in part. However, the effect of ANS on thyroid are controversial.

Patients:

A study group of 99 very low birthweight neonates (<34 weeks' gestational age) with the exception of those born more than 7 days after ANS administration were divided into a complete group ($n = 49$) whose mothers completed two doses of betamethasone and who were born more than 24 h after the completion of ANS administration, and an incomplete group ($n = 50$) who were not exposed to any ANS or were born within 24 h after the completion of ANS administration. Serum free thyroxine and thyroid stimulating hormone (TSH) levels were measured and thyrotropin-releasing hormone (TRH) stimulation tests were performed at about 2 weeks of age.

Results:

The incidence of hyperthyrotropinemia ($TSH > 15$ mIU/L) in the complete group was significantly lower than in the incomplete group (6% vs, 22%, $P = 0.023$). Exaggerated responses to TRH tests were more frequent in the incomplete group (17% vs. 44%; $P = 0.053$). TSH_{30} was significantly lower in the complete group, ($P = 0.046$). Multivariate logistic regression analysis showed that the incidence of

hyperthyrotropinemia was associated with complete ANS administration (adjusted odds ratios 0.39).

Conclusions:

ANS administration might facilitate thyroid maturation in preterm neonates.

Keywords:

Aantenatal corticosteroids, preterm, thyroid, cortisol, thyrotropin-releasing hormone

Data sharing

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Main Text File

Main text

1. | INTRODUCTION

Advances in perinatal care have improved the prognosis for preterm neonates.^{1,2} Among them, the

administration of antenatal corticosteroids (ANS) is one of the most effective. Since Liggins et al. first reported that maternal ANS administration reduced the incidence of neonatal respiratory distress syndrome (RDS) in 1972,³ its clinical efficacy has been verified in many studies.⁴⁻⁶ The beneficial effects of ANS have been reported not only in reducing the incidence of RDS, but also in reducing the incidence of mortality, intraventricular hemorrhage, periventricular leukomalacia, and necrotizing enterocolitis.^{7,8} As the mechanism of ANS in reducing the incidence of RDS is considered to involve organ maturation in the lungs by facilitating differentiation into Type 2 pulmonary epithelial cells, this effect might contribute to a reduction in other morbidities in preterm neonates, at least in part. On the other hand, the suppression of somatic cell growth by ANS might result in unfavorable effects on the somatic and developmental outcome, is of concern.^{9,10} With increasing numbers of mothers receiving ANS, it is important to examine both the favorable and unfavorable effects of this intervention.

Endocrine function is one of the key factors that might influence psychomotor development in preterm neonates.¹¹⁻¹³ Thyroid function is considered a key issue among them.¹⁴⁻¹⁶ Although preterm neonates do not often have primary hypothyroidism with elevated thyroid stimulating hormone (TSH) levels,¹⁷ preterm infants frequently show thyroidal dysfunctions. Many have transient hypothyroxinaemia of prematurity (THOP),¹⁸ however there is no consensus for the treatment with thyroid hormones. Delayed elevation of TSH is also common in preterm infants, but treatments for this condition remain controversial. Although the links between such thyroid status specific to preterm infants and subsequent neurological outcomes are tenuous at best,¹⁹ thyroid maturation might be associated with a good outcome for preterm neonates. Maturation of thyroid function is accelerated in the third trimester of pregnancy, coinciding with a cortisol surge in the fetus.^{20,21} Glucocorticoids are involved in the process.^{22,23} Therefore, we hypothesized that ANS might promote the maturation of thyroid function, in addition to organs such as the lungs. In human studies, the effects of ANS on the maturation of thyroid function is controversial: one report claimed that administration of ANS reduced thyroid dysfunction in neonates,²⁴ but others found no such effect.^{25,26} Therefore, we conducted a study to examine the effects of ANS on thyroid function in preterm neonates. We evaluated not only basal free thyroxine (FT4) and TSH levels but also TRH stimulation tests, which are

helpful in defining thyroid dysfunction in older children and full-term neonates.^{27–29} In preterm neonates, we previously reported that the hypothalamic–pituitary–thyroid (HPT) axis could respond to TRH stimulation tests appropriately even in very low birth weight neonates born at < 30 weeks of gestation at about 2 weeks after birth.³⁰ Therefore, we consider that TRH stimulation tests are helpful for defining thyroid function.

2 | METHODS

2.1 | Subjects

Preterm neonates who were born at <34 weeks of gestational age and with birth weights <1500 g, and were admitted to Kyoto University Hospital Neonatal Intensive Care Unit (NICU) between April 2008 and March 2019 were included in this retrospective study. An ANS course consisted of two 12-mg doses of betamethasone injected intramuscularly to the mothers at risk of preterm labor 24 h apart. Neonates whose mothers had thyroid diseases or major congenital anomalies, who suffered sepsis, who received steroids before 2 weeks of age or for whom some data were missing were excluded from this study. To clarify the effects of ANS, we also excluded neonates who were born more than 7 days after the initiation of ANS administration and whose mother had already received glucocorticoids other than ANS. We divided the subjects into two groups: complete and incomplete ANS treatment. It has been reported that ANS had no effect on reducing the incidence of RDS if neonates were born within 24 h after completion of a course of ANS, so the interval between ANS administration and birth is important to detect significant effects on organ maturation.³ Therefore to clarify the effect of ANS, neonates who were born within 24 h after the completion of ANS administration were assigned to the incomplete group. Thus, the complete group consisted of neonates whose mother had completed two doses of betamethasone and who were born between 24 h and 7 days after the completion of ANS administration, and the incomplete group consisted of neonates who were not exposed to any ANS or were born within 24 h after the completion of ANS administration.

Ethics approval was obtained from Kyoto University Graduate School and Faculty of Medicine Ethics Committee, and written informed parental consent was obtained before each procedure.

117

2

3

118

5

119

7

120

9

121

10

122

12

123

14

124

16

125

18

126

19

127

21

128

23

129

24

130

26

131

27

132

29

133

31

134

32

135

33

136

34

137

35

138

36

139

38

140

40

141

41

142

43

143

44

144

45

145

46

146

47

147

48

148

50

149

51

150

52

151

53

152

54

153

55

154

56

155

57

156

58

157

59

158

60

2.2 | Serum FT4 and TSH measurements and TRH stimulation tests

We measured serum FT4 and TSH values for very low birth weight (VLBW) neonates at about 2 weeks of age. Generally, we do not initiate levothyroxine sodium (LT4) treatment for neonates with low FT4 and normal TSH concentrations, considered as transient hypothyroxinemia of prematurity, but we initiate LT4 therapy for neonates with elevated TSH values (> 15 mIU/L). For neonates with TSH values <15 mIU/L, we repeat serum FT4 and TSH measurements at 1- or 2-week intervals until about 40 weeks postmenstrual age, so that neonates with delayed TSH elevation are not missed. FT4 and TSH were measured using enhanced chemiluminescence (ECLIA) kits (Roche Diagnostics, Tokyo, Japan).

In addition, we performed TRH stimulation tests for almost all VLBW neonates at about 2 weeks of age to evaluate the hypothalamic–pituitary–thyroid (HPT) axis and thyroid function during 2008–2010 and 2015–2017 among cases where parental consent for such testing was obtained. ~~As we did not perform~~ TRH stimulation tests ~~were not performed~~ during ~~the period~~ 2011–2014, ~~resulting in fewer TRH tests the number~~ ~~of infants who were performed by the tests were lower~~ than the total ~~number of~~ subjects. The test was performed as follows: 7 µg/kg TRH (Tanabe Mitsubishi Pharmaceutical Company, Osaka, Japan) was injected intravenously and serum was collected before and 30 min after the injection.^{30,31} If the TSH value at 30 min (TSH₃₀) was above 35 mIU/L, it was considered as an exaggerated response indicating thyroid dysfunction.³¹

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

2.3 | Outcomes

The primary outcome was an elevated serum TSH value (> 15 mIU/L), resulting in the initiation of LT4 Therapy. Secondary outcomes were serum TSH and FT4 levels at about 2 and 4 weeks of age, at about 40 weeks postmenstrual age and the outcomes of TRH stimulation tests.

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

2.4 | Statistical analysis

Data are expressed as medians and interquartile ranges. The Mann–Whitney nonparametric *U*-test was used to compare continuous variables, and the chi-squared test was used for analyzing categorical data. *P* < 0.05 was considered statistically significant. Multivariate logistic regression analysis was performed to adjust for

potential cofounders and identify risk factors for the incidence of hyperthyrotropinemia and TRH stimulation tests. All statistical analyses were conducted using IBM SPSS Statistics (version 20; IBM Corp., Armonk, NY, USA).

3 | RESULTS

3.1 | Profiles of the subjects

Two hundred twenty-four neonates born at <34 weeks of gestational age with birth weights < 1500g were admitted to the NICU between April 2008 and March 2019 (Fig. 1). We excluded 125 for the reasons given above, so the final enrollment was 99. Characteristics of neonates in the complete and incomplete ANS groups are shown in Table 1. There was a significant difference only in the variable “history of surgery” ($P = 0.004$). Most surgeries involved ductus arteriosus ligation. Other variables were not significantly different between the two groups.

The time from administration of ANS to delivery in the complete group was a median of 60 h (range 43 – 92), and that in the incomplete group was all within 12h. In the incomplete group, 22 neonates (44%) were not exposed to ANS.

3.2 | Thyroid function of the subjects

Regarding thyroid function, the incidence of hyperthyrotropinemia (TSH > 15 mIU/L) at about 2 weeks was significantly lower in the complete group (6% vs 22%; $P = 0.023$) although there were no significant differences in median serum TSH, FT4 values and the incidence of hypothyroxinemia (FT4 < 10.5 pmol/L ~~0.8 ng/dL~~) (Table 2). At the two later time points, there were no significant differences in median serum TSH and FT4 values between the two groups (data not shown), but in the incomplete group three neonates developed delayed elevation of TSH after 3 weeks of age (days 21, 21, and 39). We initiated LT4 therapy for neonates with hyperthyrotropinemia and adjusted the dose so that serum TSH values were < 5 mIU/L; almost all those neonates continued to be administered the drug at the time of discharge. Serum TSH values in all cases except for three with delayed TSH elevation remained < 15 mIU/L and decreased spontaneously throughout the study.

167

2

3

168

5

169

7

8

9

10

171

12

172

14

173

15

174

16

17

178

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

3.3 | Risk factors for the incidence of hyperthyrotropinemia

Variables used in the multiple logistic regression analysis were complete ANS therapy, gestational age, birth weight (SD), use of iodinated contrast agents, and history of surgery, as these are known risk factors for thyroid dysfunction. Results of the analysis are shown in Table 3. The incidence of hyperthyrotropinemia (TSH > 15 mU/L) was independently associated with complete ANS administration with an adjusted odds ratio (aOR) value of 0.39.

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

3.4 | TRH stimulation test

Outcomes of the TRH stimulation test are shown in Table 4. TSH₃₀ values in most of the subjects were > 10 mIU/L, indicating that the test had been performed correctly, and that no pituitary dysfunction was found in most of the neonates. Comparing the two groups, the TSH₃₀ level in the complete group was significantly lower than in the incomplete group (22.3 ~~μIU/ml~~ mIU/L vs 33.8 ~~μIU/ml~~ mIU/L; *P* = 0.046). This finding suggested that thyroid function of the neonates in the complete group was more mature than that in the incomplete group. As defined at 35 ~~μIU/ml~~ mIU/L, the incidence of an exaggerated response was lower in the complete group but not significantly (17% vs 44%; *P* = 0.053). The aOR value of complete ANS (by gestational age, birth weight (± SD), use of iodinated contrast agents, and history of surgery) was 0.21 (95% confidence interval, 0.041–1.09; *P* = 0.064).

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

axis, as glucocorticoids are known to have suppressive effects on this and can cause hypothyroidism.³³ However, in our study there was no difference in the serum FT4 level between the two groups, and no suppression of FT4 by ANS was found. Therefore, we consider that the decrease in TSH levels by ANS therapy indicated maturation of the HPT axis but not its suppression.

Although the mechanism by which maternal corticosteroids might affect fetal thyroid function was not evaluated in our studies, it was reported that cortisol infusion to the preterm fetus raised its hepatic, renal, and perirenal adipose tissue deiodinase (D)1 levels and reduced renal and placental D3 activities in animal studies.²² The report concluded that the prepartum cortisol surge induces tissue-specific changes in D activity. It also reported that dexamethasone infusion to pregnant animals changed the D1 and D3 activities of preterm fetuses similarly to cortisol infusion to the fetus, so ANS treatment has a maturational effect on the thyroid function of preterm fetus in addition to the preterm cortisol surge.²³ Based on these reports, we speculated that ANS might be associated with fetal thyroid maturation not only in animal models but also in humans. Thus, ANS therapy might reduce the incidence of thyroid dysfunction in preterm neonates by promoting thyroid maturation.

This study had several limitations. First, it was a relatively small retrospective study in a single institution and should be verified in a larger study. Second, in this study ANS administration might have been at a low incidence. Many pregnant women with serious problems such as abruptio placentae, non-reassuring fetal status, poor blood pressure control, and premature rupture of the membranes are transferred to our hospital just before delivery, so that the number of cases where ANS was not given in time tended to be higher. Third, TRH stimulation tests were performed only for 45% of the subjects (45/99); but the profiles of these neonates were similar to those of the total study population, as shown in Appendices 1 and 2. Considering these points, we integrated the findings with TRH stimulation tests in this study. Fourth, urinary iodine concentration was not measured in this study, although iodine deficiency or excess is one of the most common causes of hypothyroidism.³³ Japan is surrounded by ocean, and seaweed is our primary source of iodine. Thus Japan is a country with iodine sufficiency, and iodine deficiency is rarely seen.³⁴ On the contrary, iodine overexposure could be a problem. Based on these observations, iodine overexposure

during surgical treatment or with the use of iodine contrast agents is a matter of concern in discussing thyroid function. In the present study, the incidence of previous surgical treatment was lower in the complete group, which might explain the favorable effects of ANS therapy. However, there was no significant difference in the incidence of hyperthyrotropinemia between the groups with and without a history of surgery (28% vs 12%, $P = 0.09$). Furthermore, our multivariate logistic regression analysis showed that hyperthyrotropinemia was not associated with a history of surgery (Table 4). Based on these considerations, we consider that the possible contribution of iodine exposure to the incidence of hyperthyrotropinemia was minor compared with the effects of ANS therapy. Fifth, the impact of cardiorespiratory severity on thyroid dysfunction cannot be completely ruled out because the severity was not included in the variables for the multivariate analysis due to the small number of cases.

CONCLUSIONS

Here we found that complete ANS administration could reduce the incidence of hyperthyrotropinemia in preterm neonates. This might reflect maturation of thyroid function. Therefore, it is desirable that any maternal administration of ANS should be done completely, not only for its effects on the respiratory and circulatory systems of the progeny, but also for thyroid maturation in the progeny.

CONFLICT OF INTEREST

The authors do not declare any conflict of interest or financial involvement with this manuscript.

REFERENCES

1. Itabashi K, Horiuchi T, Kusuda S.et al. Mortality rates for extremely low birth weight infants born in Japan in 2005. *Pediatrics*. 2009; 123:445-450.
2. Fanaroff AA, Hack M, Walsh MC. The NICHD neonatal research network: changes in practice and outcomes during the first 15 years. *Semin Perinatol*. 2003; 27:281-287.
3. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. *Pediatrics*.1972; 50:515-525.

4. Gyamfi-Bannerman C, Thom EA. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants *N Engl J Med*. 2016; 375:486-487
5. Saccone G, Berghella V. Antenatal corticosteroids for maturity of term or near term fetuses: systematic review and meta-analysis of randomized controlled trials. *BMJ*. 2016; 355: i5044.
6. Ecker JL, Kaimal A, Mercer BM. et al. Obstetric Care consensus No. 6: Periviable Birth. *Obstet Gynecol*. 2017; 130: e187-e199.
7. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev*. 2017; 3:CD004454.
8. Leviton A, Dammann O, Allred EN. Antenatal corticosteroids and cranial ultrasonographic abnormalities. *Am J Obstet Gynecol*. 1999; 181:1007-1017.
9. Ford LR, Willi SM, Hollis BW, Wright NM. Suppression and recovery of the neonatal hypothalamic-pituitary-adrenal axis after prolonged dexamethasone therapy. *J Pediatr*. 1997; 131:722-726.
10. Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. *BMC Pediatr*. 2001; 1:1
11. Williams GR. Neurodevelopmental and neurophysiological actions of thyroid hormone. *J Neuroendocrinol*. 2008; 20:784-794.
12. Fernandez EF, Watterberg KL. Relative adrenal insufficiency in the preterm and term infant. *J Perinatol*. 2009; Suppl 2: S44-9.
13. Kawai M. Late-onset circulatory collapse of prematurity. *Pediatr Int*. 2017; 59:391-396.
14. de Zegher F, Pernasetti F, Vanhole C, Devlieger H, Van den Berghe G, Martial JA. The prenatal role of thyroid hormone evidenced by fetomaternal Pit-1 deficiency. *J Clin Endocrinol Metab*. 1995; 80:3127-3130.
15. Vulsma T, Gons MH, de Vijlder JJ. Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. *N Engl J Med*. 1989; 321:13-16.

16. Frank JE, Faix JE, Hermos RJ.et al. Thyroid function in very low birth weight infants: effects on neonatal hypothyroidism screening. *J Pediatr.* 1996; 128:548-554.
17. Kaluarachchi DC, Colaizy TT, Pesce LM, Tansey M, Klein JM. Congenital hypothyroidism with delayed thyroid-stimulating hormone elevation in premature infants born at less than 30 weeks gestation. *J Perinatol.* 2017; 37:277-282.
18. van Wassenae AG, Kok JH, de Vijlder JJ.et al. Effect of thyroxine supplementation on neurologic development in infants born at less than 30 week' gestation. *N Engl J Med.* 1997; 336:21-26.
19. Hollanders JJ, Israels J, van der Pal SM.et al. No association between transient hypothyroxinemia of prematurity and neurodevelopmental outcome in young adulthood. *J Clin Endocrinol Metab.* 2015; 100:4648-4653.
20. Thorpe-Beeston JG, Nicolaides KH, Felton CV, Butler J, McGregor AM. Maturation of the secretion of thyroid hormone and thyroid-stimulating hormone in the fetus. *N Engl J Med.* 1991; 324:532-536.
21. Dattani MT, Gevers EF. Endocrinology of fetal development. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. *Williams Textbook of Endocrinology* 13th edition: Amsterdam, Netherlands, Elsevier; 2015:858-861.
22. Forhead AJ, Curtis K, Kaptein E, Visser TJ, Fowden AL. Developmental control of iodothyronine deiodinases by cortisol in the ovine fetus and placenta near term. *Endocrinology.* 2006; 147:5988-5994.
23. Forhead AJ, Jellyman JK, Gardner DS.et al. Differential effects of maternal dexamethasone treatment on circulating thyroid hormone concentrations and tissue deiodinase activity in the pregnant ewe and fetus. *Endocrinology.* 2007; 148:800-805.
24. Kaluarachchi DC, Zhao Q, Colaizy TT. Antenatal steroids and thyroid hormone function in preterm infants. *J Perinatol.* 2018; 38:1466-1470.
25. Franklin RC, Purdie GL, O'Grady CM. Neonatal thyroid function: prematurity, prenatal steroids, and respiratory distress syndrome. *Arch Dis Child.* 1986; 61:589-592.

26. Lee JH, Kim SW, Jeon GW, Sin JB. Thyroid dysfunction in very low birth weight preterm infants. *Korean J Pediatr.* 2015; 58:224-229.
27. Foley TP Jr, Jacobs LS, Hoffman W, Daughaday WH, Blizzard RM. Human prolactin and thyrotropin concentrations in the serums of normal and hypopituitary children before and after the administration of synthetic thyrotropin-releasing hormone. *J Clin Invest.* 1972; 51:2143-2150.
28. Jacobsen BB, Andersen H, Dige-Petersen H, Hummer L. Thyrotropin response to thyrotropin-releasing hormone in full term, euthyroid and hypothyroid newborns. *Acta Paediatr Scand.* 1976; 65:433-438.
29. Jacobsen BB, Andersen H, Dige-Petersen H, Hummer L. Pituitary-thyroid responsiveness to thyrotropin-releasing hormone in preterm and small-for-gestational age newborns. *Acta Paediatr Scand.* 1977; 66:541-548.
30. Niwa F, Kawai M, Kanazawa H. et al. Hyperthyrotropinemia at 2 weeks of age indicates thyroid dysfunction and predicts the occurrence of delayed elevation of thyrotropin in very low birth weight infants. *Clin Endocrinol (Oxford).* 2012; 77:255-261.
31. Rapaport R, Sills I, Patel U. et al. Thyrotropin-releasing hormone stimulation tests in infants. *J Clin Endocrinol Metab.* 1993; 77:889-894.
32. No authors listed. Committee Opinion No. 713 Summary: Antenatal corticosteroid therapy for fetal maturation. *Obstet Gynecol.* 2017; 130:493-494.
33. Re RN, Kourides IA, Ridgway EC, Weintraub BD, Maloof F. The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin. *J Clin Endocrinol Metab.* 1976; 43:338-346.
34. Dattani MT, Gevers EF. Endocrinology of fetal development. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. *Williams Textbook of Endocrinology*. 13th edition: Amsterdam, Netherlands; 2015:423-433
35. Fuse Y. Iodine and thyroid function: historical review of goiter and the current iodine status in Japan.

Pediatr Endocrinol Rev. 2017; 14:260-270

For Peer Review

338
2
3
339
5
6
340
8
9
341
11
12
342
14
15
343
17
18
344
20
21
345
23
24
346
26
27
347
29
30
348
32
33
349
35
36
350
38
39
351
41
42
352
44
45
353
47
48
354
50
51
355
53
54
356
56
57
58
59
60

For Peer Review

TABLE 1 Characteristics of the two groups of neonates and their mothers’ medical history. Data are expressed as medians and interquartile ranges or numbers and percentages.

Clinical characteristics	Complete (<i>n</i> = 49)	Incomplete (<i>n</i> = 50)	<i>P</i>
Male, <i>n</i> (%)	24 (49)	25 (50)	0.92
GA (weeks)	28.0 (26.8–30.3)	28.6 (26.4–30.2)	0.61
BW (g)	948 (618–1225)	892 (746–1174)	0.49
Small for gestational age, <i>n</i> (%)	26 (53)	17 (34)	0.06
Caesarean section, <i>n</i> (%)	44 (90)	48 (96)	0.23
Apgar score (1 min)	5 (2–7)	4 (2–7)	0.53
Apgar score (5 min)	7 (6–9)	7 (6–9)	0.53
Postnatal steroids, <i>n</i> (%)	7 (14)	8 (16)	0.81
DOA/DOB infusion, <i>n</i> (%)	5 (10)	8 (16)	0.39
NO inhalation, <i>n</i> (%)	3 (6)	1 (2)	0.30
Use of surfactant, <i>n</i> (%)	23 (47)	30 (60)	0.14
Duration of mechanical ventilation (days)	6 (0–25)	8 (3–28)	0.38
BPD36, <i>n</i> (%)	25 (51)	19 (42)	0.26
Use of mechanical ventilation at 2 weeks of age, <i>n</i> (%)	21 (43)	21 (42)	0.93
Use of oxygen at 2 weeks of age, <i>n</i> (%)	31 (63)	36 (72)	0.35
Use of iodinated contrast agents, <i>n</i> (%)	3 (6)	6 (12)	0.31
History of surgery, <i>n</i> (%)	2 (4)	12 (24)	0.004
Intraventricular hemorrhage grade III, IV, <i>n</i> (%)	1 (2)	5 (10)	0.10

BPD36, bronchopulmonary dysplasia at 36 weeks; GA, gestational age; BW, birth weight; DOA, dopamine; DOB, dobutamine; NO, nitric oxide–

TABLE 2 Incidence of hyperthyrotropinemia, TSH and FT4 levels at about 2 weeks of age of the two groups of neonates. Data are expressed as medians and interquartile ranges or numbers and percentages.

	Complete (<i>n</i> = 49)	Incomplete (<i>n</i> = 50)	<i>P</i>
Incidence of hyperthyrotropinemia, <i>n</i> (%)	3 (6)	11 (22)	0.02
Incidence of hypothyroxinemia, <i>n</i> (%)	19 (9/47)	17 (8/47)	0.79
Postnatal days when elevated TSH was detected	14 (12.5–15)	14.5 (14–18.5)	0.70
TSH at about 2 weeks of age (mIU/L)	5.80 (3.68–10.68)	7.47 (4.23–9.05)	0.44
FT4 at about 2 weeks of age (pmol/L)	15.3 (12.5–19.2)	15.2 (11.8–18.4)	0.69

For Peer Review

TABLE 3 Multivariate logistic regression analysis on factors involved in the incidence of hyperthyrotropinemia among neonates (TSH > 15 mIU/L)

Variable	Adjusted odds ratio	95% confidence interval	<i>P</i>
Complete ANS treatment in pregnancy	0.39	0.18–0.85	0.02
Gestational age	0.79	0.60–1.04	0.09
Birth weight	0.56	0.33–0.97	0.04
Use of iodinated contrast agents	0.49	0.054–4.42	0.52
History of surgery	1.34	0.23–7.87	0.75

TABLE 4 Results of TRH stimulation tests in the two groups of neonates

	Complete (<i>n</i> = 18)	Incomplete (<i>n</i> = 27)	<i>P</i>
TSH ₃₀ (mIU/L)	22.3 (18.85–32.44)	33.8 (26.78–42.89)	0.046
TSH ₃₀ >35, <i>n</i> (%)	5 (17)	12 (44)	0.053

TSH₃₀, serum TSH level at 30 min after TRH stimulation. Data are expressed as medians and interquartile ranges or as numbers and percentages.

TSH₃₀ >35, the incidence of subjects who showed an exaggerated response higher than 35 mIU/L at 30 min after TRH stimulation.

420
2
3
421
4
5
422
7
423
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS

FIGURE 1 Flowchart of subject enrollment

ANS, antenatal corticosteroids.

For Peer Review

Appendix TABLE 1 Characteristics of the two groups undergoing TRH stimulation tests. Data are expressed as numbers and percentages or as medians and interquartile ranges.

	Complete (<i>n</i> = 18)	Incomplete (<i>n</i> = 27)	<i>P</i>
Male, <i>n</i> (%)	9 (50)	15 (55)	0.71
GA (weeks)	27.3 (26.6–28.1)	28.0 (26.0–28.8)	0.86
BW (g)	943 (607–1100)	854 (731–1121)	0.49
Small for gestational age, <i>n</i> (%)	7 (39)	6 (22)	0.23
Caesarean section, <i>n</i> (%)	16 (89)	26 (96)	0.33
Apgar score (1 min)	4 (2–6.7)	4 (2–5)	0.83
Apgar score (5 min)	7 (5.2–9)	6 (6–7)	0.65
Postnatal steroids, <i>n</i> (%)	3 (17)	2 (7)	0.33
DOA/DOB infusion, <i>n</i> (%)	3 (17)	6 (22)	0.65
NO inhalation, <i>n</i> (%)	2 (11)	0 (0)	0.08
Use of iodinated contrast agents, <i>n</i> (%)	2 (11)	2 (7)	0.31
History of surgery, <i>n</i> (%)	2 (11)	7 (26)	0.22
Intraventricular hemorrhage grade III or IV; <i>n</i> (%)	1 (5)	2 (7)	0.85

GA, gestational age; BW, birth weight; DOA, dopamine; DOB, dobutamine; NO, nitric oxide

1 Appendix **TABLE 2** Incidence of hyperthyrotropinemia, TSH and FT4 levels in mIU/L at about 2 weeks of
2
3 age in the two groups of neonates subjected to TRH stimulation tests. Data are expressed as medians and
4
5 interquartile ranges.
6

	Complete (<i>n</i> = 18)	Incomplete (<i>n</i> = 27)	<i>P</i>
Incidence of hyperthyrotropinemia, <i>n</i> (%)	1 (5)	6 (22)	0.13
Postnatal days when elevated TSH was detected	13.5 (12–14)	14 (10.5–14)	0.70
TSH (mIU/L)	6.20 (3.47–8.10)	7.61 (3.67–10.63)	0.29
FT4 (pmol/L)	14.2 (10.8–17.5)	13.5 (10.9–17.0)	0.35